Postdiagnosis Statin Use and Breast Cancer Mortality

Is postdiagnosis statin initiation associated with breast cancer mortality?In this cohort study emulating a target trial using Danish registry data from 66 952 patients with breast cancer, statin initiation within 36 months postdiagnosis was associated with lower 10-year breast cancer mortality (11.8% among those who received statins vs 13.5% among those who did not; absolute reduction, 1.7 percentage points), and all-cause mortality was 23.3% among those who received statins vs 24.5% among those who did not.These findings suggest that postdiagnosis statin use may provide a clinically meaningful survival benefit in breast cancer patients, with 59 patients needing treatment to prevent 1 additional breast cancer death at 10 years, supporting further randomized trials.

Corresponding Author: Sixten Harborg, MD, Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Entrance C, Level 1, C106, 8200 Aarhus N, Denmark (sixten.harborg@oncology.au.dk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.